Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

• US 5,854,207 A
• Filed: 02/23/1998
• Issued: 12/29/1998
• Est. Priority Date: 12/12/1995
• Status: Expired due to Term

• Current Assignee: Mariel Therapeutics, Inc.
• Original Assignee: Stryker Corporation
• Inventors: Lee, John C., Yeh, Lee-Chuan C.
• Primary Examiner(s): Nutter, Nathan M.
• Application Number:
  US09/027,873
• Time in Patent Office: 309 Days
• Field of Search: 514/2, 514/21
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61L 24/108 Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.

Claims

1. A pharmaceutical composition for inducing tissue formation in a mammal, comprising:

a) a morphogenic protein capable of inducing tissue formation when accessible to a progenitor cell in the mammal;

b) a morphogenic protein stimulatory factor selected from the group consisting of hormones, cytokines, peptides and growth factors, said factor capable of stimulating the ability of the morphogenic protein to induce tissue formation from the progenitor cell; and

c) a pharmaceutically acceptable carrier;

with the proviso that when the progenitor cell is an osteoblast stimulated to form bone and the morphogenic protein is a BMP homodimer, TGF-β

or activin, the MPSF may not be estrogen or calcitonin;

when the progenitor cell is an osteoblast stimulated to form bone and the morphogenic protein is a BMP homodimer or TGF-β

, the MPSF may not be FGF, IGF-II, PDGF or vitamin D; and

when the progenitor cell is an osteoblast stimulated to form bone and the morphogenic protein is a homodimer of BMP-2 or BMP-3, the MPSF may not be parathyroid hormone.

2. The composition according to claim 1, wherein

the morphogenic protein comprises a pair of subunits disulfide bonded to produce a dimeric species and wherein at least one of the subunits comprises a polypeptide belonging to the BMP protein family.

3. The composition according to claim 1, wherein the morphogenic protein is an osteogenic protein.

4. The composition according to claim 3 osteogenic protein is capable of inducing the progenitor cell to form endochondral or intramembranous bone.

5. The composition according to claim 3, wherein the osteogenic protein is capable of inducing the progenitor cell to form cartilage.

6. The composition according to any one of claims 1-3, wherein the morphogenic protein is capable of inducing the progenitor cell to form tissue tendon/ligament-like or neural-like tissue.

7. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises a polypeptide selected from the group consisting of:

BMP-2, BMP-4, BMP-5, BMP-6, BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, and BMP-13, COP-5, COP-7.

8. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises a polypeptide selected from the group consisting of OP-1, BMP-2, BMP-4 and BMP-6.

9. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1.

10. The composition according to claim 2, wherein the dimer is a homo- or a heterodimer comprising at least one BMP-2 or OP-1 (BMP-7) subunit.

11. The composition according to any one of claims 1-3, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting of:

insulin-like growth factor I (IGF-I), estradiol, fibroblast growth factor (FGF), growth hormone (GH), growth and differentiation factor (GDF), hydrocortisone (HC), insulin, progesterone, parathyroid hormone (PTH), vitamin D, retinoic acid and IL-6.

12. The composition according to any one of claims 1-3, wherein the morphogenic protein stimulatory factor comprises an agent that increases IGF-I bioactivity in the mammal.

13. The composition according to any one of claims 1-3, wherein the morphogenic protein stimulatory factor is present in an amount capable of synergistically stimulating the ability of the morphogenic protein to induce tissue formation in the mammal.

14. The composition according to any one of claims 1-3, wherein the morphogenic protein is present at a concentration of at least about 1 ng/ml, and the morphogenic protein stimulatory factor is present at a concentration of at least about 0.01 ng/ml.

15. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises IGF-I at a concentration from about 0.1 ng/ml to about 50 ng/ml.

16. The composition according to claim 15, comprising 200 ng/ml of OP-1 and 25 ng/ml of IGF-I.

17. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises estradiol at a concentration of from about 0.05 nM to about 1000 nM.

18. The composition according to claim 17, comprising about 200 ng/ml of OP-1 and about 5 nM estradiol.

19. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises growth hormone at a concentration of from about 5 ng/ml to about 1000 ng/ml.

20. The composition according to claim 19, comprising about 200 ng/ml of OP-1 and about 500-1000 ng/ml growth hormone.

21. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises hydrocortisone at a concentration of from about 0.05 nM to about 5.0 nM.

22. The composition according to claim 21, comprising about 200 ng/ml OP-1 and about 0.5-5.0 nM hydrocortisone.

23. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises insulin at a concentration of from about 0.01 nM to about 1000 nM.

24. The composition according to claim 23, comprising about 200 ng/ml OP-1 and about 0.05 nM insulin.

25. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises parathyroid hormone at a concentration of from about 10 nM to about 1000 nM.

26. The composition according to claim 25, comprising about 200 ng/ml OP-1 and about 25-200 nM parathyroid hormone.

27. The composition according to any one of claims 1-3, wherein the morphogenic protein comprises OP-1 at a concentration of from about 1 ng/ml to about 500 ng/ml and the morphogenic protein stimulatory factor comprises progesterone at a concentration of from about 0.05 nM to about 1000 nM.

28. The composition according to claim 27, comprising about 200 ng/ml OP-1 and about 0.05-5 nM progesterone.